$ADAP News
Last published 1y ago
- 1y agoADAPAdaptimmune Therapeutics plc (ADAP) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoADAPAdaptimmune Therapeutics plc (ADAP) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoADAPAdaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid TumorBusiness WireApproved for advanced MAGE-A4+synovial sarcoma in adults with certain HLA types who have received prior chemotherapy TECELRA is the first new treatment option for people with synovial sarcoma in more than a
- 2y agoADAPGLPGGalapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indicationsGlobeNewswireAdaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform
- 2y agoADAPAdaptimmune Therapeutics plc (ADAP) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoADAPBDTXDVASTOKGarry Menzel joins GHO Capital as Operating PartnerGlobeNewswireGarry Menzel joins GHO Capital as Operating Partner Former CEO of TCR² Therapeutics with significant investment and operating experience to support deal origination and provide best in class services to pioneering
- 2y agoADAPAdaptimmune Therapeutics plc (ADAP) Q4 2023 Earnings Call TranscriptEarnings Call Transcripts
- 3y agoADAPTCRRAdaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid TumorsGlobeNewswireCompelling clinical data with clear paths to products and multiple near‐term value-creating catalysts Complementary technology platforms designed to treat solid tumors which represents a substantial market opportunity
- 3y agoADAPSPEARHEAD-3 Pediatric Study - NCT05642455ClinicalTrials.govEvaluate safety and tolerability of afamitresgene autoleucel and determination of an optimal tolerated dose range determined by incidence, severity and duration of Treatment Emergent Adverse Events and Incidence and DLTs as assessed by Investigator., Efficacy: Objective response rate (ORR) assessed by investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (or by International ...
- 4y agoADAPADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3) - NCT05601752ClinicalTrials.govTo evaluate the anti-tumor activity of genetically modified autologous T-cells (ADP-A2M4CD8) as monotherapy and in combination with nivolumab in HLA-A*02 positive subjects with MAGE-A4 positive recurrent ovarian cancer, To evaluate safety and tolerability of ADP-A2M4CD8 as monotherapy or in combination with nivolumab, To evaluate safety of ADP-A2M4CD8 as monotherapy or in combination with nivoluma ...
- 4y agoADAPPreclinical Proof-of-Concept Data Supporting Future Clinical Development of Two New Cell Therapies Being Presented by Adaptimmune at ASGCTGlobeNewswire- New next-gen SPEAR T-cells (ADP-A2M4N7X19) designed to enhance depth and durability of clinical response demonstrated enhanced proliferation, survival, and recruitment of immune cells in vitro - - Engineered TILs (ADP-TILIL7) intended to improve cli
- 4y agoADAPAdaptimmune Reports First Quarter Financial Results and Business UpdateGlobeNewswire- Pooled data from Cohort 1 of the SPEARHEAD-1 trial and the Phase 1 trial of afami-cel in patients with sarcoma to be presented as a poster at ASCO - - Preclinical data for two novel next-generation T-cell therapies to be presented in two posters at
- 4y agoADAPAdaptimmune Announces Appointment of Joanna Brewer as Chief Scientific OfficerGlobeNewswirePHILADELPHIA and OXFORDSHIRE, United Kingdom, May 04, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Dr. Joanna (Jo) Brewer as Chief Scientific Officer
- 4y agoADAPAdaptimmune to Report Q1 2022 Financial Results and Business Updates on Monday, May 9, 2022GlobeNewswirePHILADELPHIA and OXFORDSHIRE, United Kingdom, April 28, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the first quarter ende
- 4y agoADAPAdaptimmune Presents MAGE-A4 Expression Data from its Screening Protocol at AACR Confirming Expression Across a Broad Range of Solid TumorsGlobeNewswire- Data from multiple solid tumor indications confirms that MAGE-A4 is a broadly expressed cancer target for SPEAR T-cell therapy - - Rate of eligible MAGE-A4 expression was 67% for synovial sarcoma, and ranged from 20%-35% for squamous cell lung, blad
- 4y agoADAPMULNNOKTRQ+1Thinking about buying stock in Turquoise Hill Resources, Mullen Automotive, Frontier Group, Adaptimmune Therapeutics, or Nokia?PR NewswireNEW YORK, March 14, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TRQ, MULN, ULCC, ADAP, and NOK.
- 4y agoADAPAdaptimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Business UpdateGlobeNewswire- SPEARHEAD-1 met its primary endpoint - planning for afami-cel BLA submission in Q4 2022 for people with synovial sarcoma - - Moving to late-phase development with ADP-A2M4CD8: SURPASS-2 initiated in esophageal and EGJ cancers; initiating SURPASS-3 i
- 4y agoADAPAdaptimmune to Report Q4 and Full Year 2021 Financial Results and Business Updates on Monday, March 14, 2022GlobeNewswirePHILADELPHIA and OXFORDSHIRE, United Kingdom, March 08, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the fourth quarter and
- 4y agoADAPBLUENVSTSVTAdaptimmune Announces Appointment of Cintia Piccina as Chief Commercial OfficerGlobeNewswirePHILADELPHIA and OXFORDSHIRE, United Kingdom, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Cintia Piccina as Chief Commercial Officer effect
- 5y agoADAPTranslational Data at SITC 2021 from Adaptimmune's Phase 1 SURPASS Trial Indicate Adding AKTi to Manufacturing May Contribute to Sustained Antitumor Activity of Next-gen SPEAR T-cellsGlobeNewswire- Inhibition of AKT signaling during ex vivo T-cell expansion phase of manufacturing provides further proliferative potential and enhanced memory phenotype of next-gen SPEAR T-cells - - Data suggests that addition of AKT inhibitor (AKTi) during manufa
- 5y agoADAPAdaptimmune Reports Positive Results from its Pivotal SPEARHEAD-1 Trial in Patients with Synovial Sarcoma and MRCLS at CTOSGlobeNewswire- SPEARHEAD-1 trial will meet its primary endpoint and data will be used to support BLA filing for afami-cel next year - - The overall response rate (ORR) per Independent Review was 34% (36% in patients with synovial sarcoma and 25% for patients w
- 5y agoADAPAdaptimmune Reports Third Quarter Financial Results and Business UpdateGlobeNewswire- Strategic Collaboration Agreement with Genentech has started after expiration of HSR waiting periods; Adaptimmune set to receive $150 million upfront payment - - SURPASS trial data at ESMO confirms potential of MAGE-A4 franchise across a range of tu
- 5y agoADAPAdaptimmune Therapeutics plc (ADAP) Q3 2021 Earnings Call TranscriptEarnings Call TranscriptsADAP earnings call for the period ending September 30, 2021.
- 5y agoADAPAdaptimmune to Report Q3 2021 Financial Results and Business Update on Thursday, November 4, 2021GlobeNewswirePHILADELPHIA and OXFORDSHIRE, United Kingdom, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide a business update for the third quarter ende
- 5y agoADAPAdaptimmune to Present Data Updates at Upcoming CTOS and SITC MeetingsGlobeNewswire- Clinical update and translational data from SPEARHEAD-1 in patients with synovial sarcoma and MRCLS to be presented at CTOS - - The Company will host its first virtual medical symposium at CTOS - - Translational data from Phase 1 SURPASS trial to
- 5y agoADAPARECFCELMVST+1Thinking about buying stock in Microvast, FuelCell Energy, Workhorse Group, Adaptimmune Therapeutics, or American Resources?PR NewswireNEW YORK, Sept. 15, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MVST, FCEL, WKHS, ADAP, and AREC.
- 5y agoADAPATERENDPHEPA+1Thinking about buying stock in Leap Therapeutics, Aterian, Hepion Pharmaceuticals, Adaptimmune Therapeutics, or Endo International?PR NewswireNEW YORK, Sept. 13, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LPTX, ATER, HEPA, ADAP, and ENDP.
- 5y agoADAPAdaptimmune Announces Clinical Responses across Five Solid Tumor Indications with an Overall Response Rate of 36% and Promising Early Durability from its Next-Generation SURPASS TrialGlobeNewswire- Confirmed complete response in ovarian cancer, and confirmed partial responses in ovarian, head and neck, esophagogastric junction, bladder, and synovial sarcoma cancers - - Majority of patients experienced antitumor activity with a disease control
- 5y agoABCLADAPGLYCQURE+1Thinking about buying stock in Adaptimmune Therapeutics, Ziopharm Oncology, Uniqure NV, GlycoMimetics, or AbCellera Biologics?PR NewswireNEW YORK, Sept. 7, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ADAP, ZIOP, QURE, GLYC, and ABCL.
- 5y agoADAPRHHBYAdaptimmune Enters into a Strategic Collaboration with Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell TherapiesGlobeNewswire- Combining both companies' cell therapy leadership and expertise, the collaboration covers the research and development of "off-the-shelf" cell therapies for up to five shared cancer targets and the development of a novel allogeneic personalized cell th
- 5y agoADAPAdaptimmune Updates Data from its Phase 1 Trial for Liver Cancer at ILCA Showing Clinical BenefitGlobeNewswire- One complete response, and a disease control rate of 64% with stable disease for ≥16 weeks in two patients, as of the data cutoff - - Data presented today at the International Liver Cancer Association meeting at 12:25 p.m. CET - PHILADELPHIA an
- 5y agoADAPAdaptimmune Reports Second Quarter Financial Results and Business UpdateGlobeNewswire- SPEARHEAD-1 data presented at ASCO with overall response rate of 39.3% in synovial sarcoma and MRCLS; on track to file BLA for afami-cel next year - - SURPASS trial data from 23 evaluable patients to be presented at ESMO - - ADP-A2AFP Phase 1 tri
- 5y agoADAPAdaptimmune Therapeutics plc (ADAP) Q2 2021 Earnings Call TranscriptEarnings Call TranscriptsADAP earnings call for the period ending June 30, 2021.
- 5y agoADAPAdaptimmune to Report Q2 2021 Financial Results and Business Update on Monday, August 9, 2021GlobeNewswirePHILADELPHIA and OXFORDSHIRE, United Kingdom, July 28, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide a business update for the second quarter end
- 5y agoADAPONCTONCYPRPO+1Thinking about buying stock in Oncternal Therapeutics, Polarityte, Adaptimmune Therapeutics, Oncolytics Biotech, or Precipio?PR NewswireNEW YORK, May 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ONCT, PTE, ADAP, ONCY, and PRPO. To
- 5y agoADAPTwo Complete Responses and Response Rate of 41% for People with Synovial Sarcoma Reported at ASCO in Adaptimmune's Phase 2 SPEARHEAD-1 TrialGlobeNewswire- Data will support BLA filing for afamitresgene autoleucel next year - - Responses observed across a broad range of antigen expression - - Initial safety and durability are encouraging - PHILADELPHIA and OXFORDSHIRE, United Kingdom, May 19, 20
- 5y agoADAPFirst Preclinical Data from Adaptimmune's Mesothelin HiT Program at ASGCT Demonstrate Antigen-specific Tumor Cell Killing in vitro and Complete Tumor Regression in an Animal ModelGlobeNewswire- Preclinical data validate that human T-cells expressing a TCR targeting mesothelin, independent of HLA recognition, can kill human tumor cells - - HiT works as well, or better than, a TRuC construct targeting mesothelin in preclinical studies - P
- 5y agoADAPAdaptimmune Reports First Quarter Financial Results and Business UpdateGlobeNewswire- Initial SPEARHEAD-1 data to be presented in an oral presentation at ASCO - - First preclinical update from HLA-independent TCR (HiT) targeting mesothelin at ASGCT - - Enrollment momentum in SURPASS and ADP-A2AFP clinical trials increased in Q1 -
- 5y agoADAPAdaptimmune to Present First Preclinical Data from its HLA-independent TCR (HiT) Platform at ASGCTGlobeNewswirePHILADELPHIA and OXFORDSHIRE, United Kingdom, April 27, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in cell therapy to treat cancer, will report initial preclinical data from its HLA Independent TCR (HiT) targeting mes
- 5y agoADAPAdaptimmune to Report Q1 2021 Financial Results and Business Update on Thursday, May 6, 2021GlobeNewswirePHILADELPHIA and OXFORDSHIRE, United Kingdom, April 22, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide a business update for the first quarter end
- 5y agoADAPAdaptimmune Reports Fourth Quarter / Full Year 2020 Financial Results and Business UpdateGlobeNewswire- Outlined strategy to build integrated cell therapy company and the Company’s “2-2-5-2” five-year core value drivers - - Reported compelling durable responses in patients with synovial sarcoma,...
- 5y agoADAPICLRADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2) - NCT04752358ClinicalTrials.govEfficacy: Overall Response Rate (ORR), Number of subjects with treatment -related adverse events (AEs), including serious adverse events (SAEs) as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, Efficacy: Best overall response (BOR), (and 6 more...)
- 5y agoADAPAdaptimmune to Report Fourth Quarter/ Full Year 2020 Financial Results and Business Updates on Thursday, February 25, 2021GlobeNewswirePHILADELPHIA and OXFORDSHIRE, United Kingdom, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results...
- 5y agoADAPAdaptimmune to Showcase Market Potential for SPEAR T-cell Portfolio and Pipeline with Multiple Cell Therapy Platforms During Virtual Investor DayGlobeNewswire- SPEARHEAD-1 enrolment on track; planning to launch ADP-A2M4 in 2022 in the US for people with synovial sarcoma - - Next registration directed trial initiating with ADP-A2M4CD8 in 1H 2021 for...
- 5y agoADAPDurable Responses with ADP-A2M4 in Synovial Sarcoma with Confirmed Responses in 44% of Patients and Disease Control Rate of 94% Presented at CTOSGlobeNewswire- Data support confidence in SPEARHEAD-1 as a registrational trial - - Projected to complete recruitment of all patients in Q1 2021 - - Median duration of response was 28 weeks with ongoing...
- 6y agoADAPAdaptimmune to Host Virtual Investor Day on Friday, November 20thGlobeNewswirePHILADELPHIA and OXFORDSHIRE, United Kingdom, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will host a virtual Investor...
- 6y agoADAPTwo Confirmed Responses and Five out of Six Patients with Initial Tumor Reductions from Early Dose Cohorts of SURPASS Trial, Presented at SITCGlobeNewswire- Data support continued development of ADP-A2M4CD8 - - On track to start Phase 2 trial in gastroesophageal cancers in the first half of 2021 - PHILADELPHIA, Pa. and OXFORDSHIRE, UK., Nov. 09, 2020...
- 6y agoADAPAdaptimmune Reports Q3 Financial Results and Business UpdateGlobeNewswire- Data from Phase 1 Trial with ADP-A2AFP in liver cancer presented at ILC confirm safety profile and demonstrate potential benefit for patients - - Safety and response data from dose escalation...
- 6y agoADAPAdaptimmune to Report Q3 Financial Results and Business Update on Thursday, November 5, 2020GlobeNewswirePHILADELPHIA and OXFORDSHIRE, U.K., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide...
- 6y agoADAPAdaptimmune Provides Full Contents of its SITC Abstract for the Phase 1 SURPASS TrialGlobeNewswirePHILADELPHIA and OXFORDSHIRE, United Kingdom, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in cell therapy to treat cancer is aware of the...